Finch Therapeutics Group, Inc.
FNCHDelisted Oct 31, 2024- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001733257
Finch Therapeutics Group, Inc. was delisted on Oct 31, 2024; its insiders filed their last Form 4 on Jun 10, 2024; no institution reported holding it in 13F filings for Q3 2024; no superinvestor held it.
13F holders, Q3 2023
Institutional positions in Finch Therapeutics Group, Inc. as of Sep 30, 2023. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 18
- +1 vs. Q2 2023
- Shares held
- 243.6K
- −3.21K (−1.3%) vs. Q2 2023
- Total value
- $1.37M
- −$789.3K (−36.6%) vs. Q2 2023
- New holders
- 2
- 1 more added
- Sold out
- 1
- 4 more reduced
Compare with Q2 2023: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting FNCH on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 0 | $0 |
| Q1 2026 | 0 | $0 |
| Q4 2025 | 0 | $0 |
| Q3 2025 | 0 | $0 |
| Q2 2025 | 0 | $0 |
| Q1 2025 | 0 | $0 |
| Q4 2024 | 0 | $0 |
| Q3 2024 | 0 | $0 |
| Q2 2024 | 1 | $29.1K |
| Q1 2024 | 11 | $338.2K |
| Q4 2023 | 17 | $754.7K |
| Q3 2023 | 18 | $1.37M |
| Q2 2023 | 17 | $2.16M |
| Q1 2023 | 33 | $3.75M |
| Q4 2022 | 40 | $4.60M |
| Q3 2022 | 43 | $16.8M |
| Q2 2022 | 47 | $28.0M |
| Q1 2022 | 53 | $53.1M |
| Q4 2021 | 51 | $115.0M |
| Q3 2021 | 45 | $106.8M |
| Q2 2021 | 46 | $77.2M |
| Q1 2021 | 36 | $108.9M |
Institutions, Q3 2023
Shares, value and share of portfolio for each institution holding Finch Therapeutics Group, Inc.; share changes are against Q2 2023.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Baupost Group LLCSuperinvestorBaupost Group | 67,296 | $349.0K | 0.01% | 00.0% | Unchanged |
| Susquehanna International Group, LLP | 59,028 | $301.0K | 0.00% | 00.0% | Unchanged |
| Avenir Management Company, LLC | 45,650 | $236.5K | 0.54% | −9,795−17.7% | Reduced |
| Lake Street Advisors Group, LLC | 21,206 | $222.0K | 0.01% | 00.0% | Unchanged |
| Vanguard Group Inc | 35,939 | $186.2K | 0.00% | +3,263+10.0% | Added |
| Ikarian Capital, LLC | 6,892 | $35.1K | 0.01% | −1,025−12.9% | Reduced |
| MSD Partners, L.P. | 5,113 | $26.5K | 0.00% | +5,113 | New |
| Bleichroeder LP | 971 | $5.03K | 0.00% | 00.0% | Unchanged |
| Ancora Advisors, LLC | 533 | $2.76K | 0.00% | 00.0% | Unchanged |
| Tower Research Capital LLC (TRC) | 439 | $2.27K | 0.00% | −218−33.2% | Reduced |
| BlackRock Inc. | 341 | $1.77K | 0.00% | 00.0% | Unchanged |
| Morgan Stanley | 123 | $637 | 0.00% | 00.0% | Unchanged |
| Steward Partners Investment Advisory, LLC | 75 | $389 | 0.00% | 00.0% | Unchanged |
| Wells Fargo & Company | 6 | $31 | 0.00% | 00.0% | Unchanged |
| Moisand Fitzgerald Tamayo, LLC | 3 | $16 | 0.00% | +3 | New |
| UBS Group AG | 2 | $10 | 0.00% | −541−99.6% | Reduced |
| Royal Bank of Canada | 27 | $0 | 0.00% | 00.0% | Unchanged |
| Cutler Group LP | 3 | $0 | 0.00% | 00.0% | Unchanged |
| Bank of America Corp | 0 | $0 | 0.00% | −7−100.0% | Sold out |